Abingdon Health PLC (GB:ABDX)
LSE:ABDX
Want to see GB:ABDX full AI Analyst Report?
ABDX Stock Chart & Stats
6.25 p
0.20 p(2.50%)
At close: 4:00 PM EST
6.25 p
0.20 p(2.50%)
Day’s Range― - ―
52-Week Range5.10 p - 11.00 p
Previous CloseN/A
Volume7.61K
Average Volume (3M)78.74K
Market Cap
£21.34M
Enterprise Value13.70M
Total Cash (Recent Filing)£3.71M
Total Debt (Recent Filing)£948.00K
Price to Earnings (P/E)―
Beta0.04
Next Earnings
Nov 18, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding251,077,850
10 Day Avg. Volume45,332
30 Day Avg. Volume78,736
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.84
Price to Sales (P/S)3.04
P/FCF Ratio-7.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£12.18M
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthAbingdon Health shows sustained top-line expansion (noted 23.61% growth), reflecting durable demand for lateral flow diagnostics and contract services. Persistent revenue growth supports scale economics, underpins long-term commercial traction, and increases the addressable opportunity for contract manufacturing contracts.
Specialized Contract Manufacturing ModelThe company’s business model centers on specialized lateral flow assay development and contract manufacturing, creating recurring B2B revenue streams. Technical know-how, manufacturing capacity, and regulatory experience are structural advantages that drive customer stickiness and higher switching costs over the medium term.
Manageable Leverage On Balance SheetA relatively low debt-to-equity ratio provides financial flexibility to fund manufacturing scale-up or R&D without immediate refinancing pressure. For a loss-making but growing diagnostics manufacturer, modest leverage reduces solvency risk and preserves optionality to invest in capacity or secure long-term contracts.
Bears Say
Persistent Unprofitability And Weak MarginsThe company continues to report negative net profit and EBIT margins, indicating structural difficulty converting revenue into operating profit. Without improving margins, long-term reinvestment and sustainable returns are compromised, pressuring free cash generation and shareholder value creation over the medium term.
Negative Operating Cash FlowDespite positive free cash flow growth, operating cash flow is negative, signalling that core operations are not generating consistent cash. This structural cash conversion issue may force reliance on external financing or equity raises, constraining investment pacing and increasing financing risk over the next several quarters.
Declining Gross MarginA falling gross margin points to worsening unit economics from pricing pressure, higher input costs, or lower-margin contract mix. If persistent, margin erosion undermines operating leverage from revenue growth and makes profitability recovery harder, reducing the durability of business model improvements.
Abingdon Health PLC News
ABDX FAQ
What was Abingdon Health PLC’s price range in the past 12 months?
Abingdon Health PLC lowest share price was 5.10 p and its highest was 11.00 p in the past 12 months.
What is Abingdon Health PLC’s market cap?
Abingdon Health PLC’s market cap is £21.34M.
When is Abingdon Health PLC’s upcoming earnings report date?
Abingdon Health PLC’s upcoming earnings report date is Nov 18, 2026 which is in 202 days.
How were Abingdon Health PLC’s earnings last quarter?
Abingdon Health PLC released its earnings results on Mar 17, 2026. The company reported -0.004 p earnings per share for the quarter, beating the consensus estimate of -0.006 p by 0.002 p.
Is Abingdon Health PLC overvalued?
According to Wall Street analysts Abingdon Health PLC’s price is currently Overvalued.
Does Abingdon Health PLC pay dividends?
Abingdon Health PLC does not currently pay dividends.
What is Abingdon Health PLC’s EPS estimate?
Abingdon Health PLC’s EPS estimate is <0.01.
How many shares outstanding does Abingdon Health PLC have?
Abingdon Health PLC has 251,077,850 shares outstanding.
What happened to Abingdon Health PLC’s price movement after its last earnings report?
Abingdon Health PLC reported an EPS of -0.004 p in its last earnings report, beating expectations of -0.006 p. Following the earnings report the stock price went down -3.03%.
Which hedge fund is a major shareholder of Abingdon Health PLC?
Currently, no hedge funds are holding shares in GB:ABDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Abingdon Health PLC
Abingdon Health PLC (ABDX) is a UK-based company specializing in the development and manufacture of rapid diagnostic tests. The company focuses on providing innovative solutions in the healthcare sector, particularly in the fields of infectious diseases, including COVID-19 testing, and other point-of-care testing applications. Abingdon Health aims to enhance patient outcomes through its high-quality, reliable diagnostics that are designed for use in various settings, ranging from hospitals to home testing.
Technical Analysis
Circassia Pharmaceuticals
―
EKF Diagnostics Holdings
―
Genedrive
―
Omega Diagnostics
―
Renalytix
―
Options Prices
Currently, No data available
---